This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Insights Insights
| less than a minute read

Medical Cannabis in Georgia: Federal Policy Effects on State Industries

I discuss the impact that the U.S. Drug Enforcement Administration’s potential reclassification of cannabis would affect Georgia’s medical cannabis industry in his article published by Cannabis Industry Journal.

In particular, I consider three key areas of impact:

(1) How Georgia medical cannabis distributors would operate within this new regulatory framework;

(2) How this change would affect registered Georgia patients who are either currently purchasing medical cannabis or are planning to do so; and

(3) Whether this reclassification would cause big pharmaceutical companies to enter Georgia’s medical cannabis market, and if so, how.

The DEA currently lists cannabis as a Schedule I drug, which the CSA defines as drugs having no currently accepted medical use and a high potential for abuse. It appears, however, that the DEA may soon reconsider its current Schedule I classification of cannabis.


cannabis, insights, snyder_reggie